key: cord-1022744-nyvm5lkq
authors: Vaira, Luigi Angelo; Lechien, Jerome R.; Dore, Stefano; Boccaletti, Riccardo; Saussez, Sven; De Riu, Giacomo
title: Specific Therapy of Olfactory Disorders in COVID-19 Patients is Essential for the Prevention of Long-term Dysfunction
date: 2021-08-22
journal: Indian J Otolaryngol Head Neck Surg
DOI: 10.1007/s12070-021-02818-z
sha: bbd1ed34c7927bd37346edb9d382af23716202d9
doc_id: 1022744
cord_uid: nyvm5lkq

nan

authors' intent must be commended and we would like to enrich the debate raised by this article with some information that emerged from the experience we have gained in recent months on olfactory disorders in COVID-19 patients.

First, the need to implement specific therapies is confirmed by the fact that the first prospective studies with long-term follow-up are finding the persistence of severe olfactory disturbances in 5.5-11% of patients 6 months after infection [2, 3] . Such a high frequency, given the high prevalence of infection in the general population, means that in the near future we will have a huge number of patients with long-term morbidity seeking assistance.

The first pathological studies in patients with long-term COVID-19 related anosmia revealed an inflammatorybased destruction of the olfactory epithelium (OE) with involvement of the basal cells and loss of the regenerative potential of the OE [4] . Although in most patients this inflammation allows the regeneration of the OE and the recovery of the sense of smell within a few weeks, in some cases the inflammatory process can persist even after the resolution of the infection, progressively and irreparably damaging the OE. Unfortunately, the risk factors for the development of a long-term olfactory disorder have not yet been identified.

However, these recent pathogenic findings have provided the rationale for the use of systemic and local corticosteroids for the treatment of persistent COVID-19 related olfactory disorders [5] . This specific therapy is all the more effective the earlier it is started. Considering that the use of corticosteroids in patients with mild and moderate COVID-19, we believe it is indicated to postpone the initiation of therapy after the nasopharyngeal swab become negative. Future studies will be needed to establish safety 

Otorhinolaryngological manifestations and its management in COVID 19 patients

Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19

Six-month smell and taste recovery rates in COVID-19 patients: a prospective psychophysical study

Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia

Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients